Duration and cessation of antimicrobial treatment

Journal of Hospital Medicine

Volumn 7, Issue SUPPL. 1, 2012, Pages

  File, Thomas M ^a,b  

^a Northeast Ohio Medical University   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

Author keywords

Antimicrobial resistance; Case studies; Catheter related bloodstream infection; Clinical practice guidelines; Complicated intra abdominal infection; Healthcare associated pneumonia; Hospital acquired pneumonia; Short course therapy; Ventilator acquired pneumonia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; ERTAPENEM; LINEZOLID; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ASCITES; BACTEREMIA; BACTERIAL PERITONITIS; CATHETER INFECTION; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED INTRAABDOMINAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CULTURE NEGATIVE NEUTROCYTIC ASCITES; DIVERTICULITIS; DRUG COST; DRUG DETERMINATION; HEALTHCARE ASSOCIATED PNEUMONIA; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION; INFECTION RISK; MORTALITY; PATIENT CARE; PATIENT COMPLIANCE; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SPONTANEOUS BACTERIAL PERITONITIS; SUPERINFECTION; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; AGED; BACTERIAL PNEUMONIA; CASE REPORT; CROSS INFECTION; DRUG EFFECT; FEMALE; MALE; MIDDLE AGED; PHYSIOLOGY; TIME; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CATHETER-RELATED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84855301775     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.988     Document Type: Review

References (93)

1. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006; 42( suppl 2): S82-S89.
2. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008; 6: 751-763.
3. Sipahi OR. Economics of antibiotic resistance. Expert Rev Anti Infect Ther. 2008; 6: 523-539.
4. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 1999; 43: 1379-1382.
5. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010; 340: c2096.
6. Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics. 1999; 103: E28.
7. Martin SJ, Micek ST, Wood GC. Antimicrobial resistance: consideration as an adverse drug event. Crit Care Med. 2010; 38: S155-S161.
8. Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med. 2006; 119: 526.e519-526.525.
9. Johnson L, Sabel A, Burman WJ, et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med. 2008; 121: 876-884.
10. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2006; 27: 893-900.
11. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005; 41: 435-440.
12. Madaras-Kelly KJ, Remington RE, Lewis PG, Stevens DL. Evaluation of an intervention designed to decrease the rate of nosocomial methicillin-resistant Staphylococcus aureus infection by encouraging decreased fluoroquinolone use. Infect Control Hosp Epidemiol. 2006; 27: 155-169.
13. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003; 289: 885-888.
14. Rogues AM, Dumartin C, Amadeo B, et al. Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol. 2007; 28: 1389-1395.
15. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med. 2002; 162: 1515-1520.
16. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993; 119: 353-358.
17. Regal RE, DePestel DD, VandenBussche HL. The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to beta-lactams in a large teaching hospital. Pharmacotherapy. 2003; 23: 618-624.
18. Tsai HT, Wang JT, Chen CJ, Chang SC. Association between antibiotic usage and subsequent colonization or infection of extensive drug-resistant Acinetobacter baumannii: a matched case-control study in intensive care units. Diagn Microbiol Infect Dis. 2008; 62: 298-305.
19. Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents. 2005; 26: 463-472.
20. Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother. 2004; 48: 224-228.
21. Lepper PM, Grusa E, Reichl H, Hogel J, Trautmann M. Consumption of imipenem correlates with beta-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2002; 46: 2920-2925.
22. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009; 53: 1983-1986.
23. File TM Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis. 2004; 39( suppl 3): S159-S164.
24. Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin Pharmacother. 2008; 9: 561-575.
25. Perez-Gorricho B, Ripoll M. Does short-course antibiotic therapy better meet patient expectations? Int J Antimicrob Agents. 2003; 21: 222-228.
26. Kuti JL, Shore E, Palter M, Nicolau DP. Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines. Semin Respir Crit Care Med. 2009; 30: 102-115.
27. World Health Organization (WHO) report on infectious diseases 2000. Overcoming antimicrobial resistance. Chapter 5. Call to action: A massive effort to provide proper treatment. Available at: Accessed January 14, 2011.
28. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH. Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. Infectious Diseases Society of America. Clin Infect Dis. 1997; 25: 574-583.
29. Craven DE, McQuillen DP, Ooi WW, Jacoby GA, Raels EL, Steger Craven K. Shorter-course antibiotic therapy (SCAT): principles, current data, and caveats. In: Owens RCJ, Lautenbach E, editors. Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures. New York, NY: Informa Healthcare; 2008: 337-370.
30. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011; 52: e103-e120.
31. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006; 55: 1-94.
32. D'Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother. 2005; 49: 4035-4041.
33. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis. 2003; 37: 752-760.
34. O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis. 1998; 17: 828-833.
35. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest. 1996; 110: 965-971.
36. Chastre J, Luyt CE, Combes A, Trouillet JL. Use of quantitative cultures and reduced duration of antibiotic regimens for patients with ventilator-associated pneumonia to decrease resistance in the intensive care unit. Clin Infect Dis. 2006; 43( suppl 2): S75-S81.
37. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003; 290: 2588-2598.
38. Hedrick TL, Evans HL, Smith RL, et al. Can we define the ideal duration of antibiotic therapy? Surg Infect (Larchmt). 2006; 7: 419-432.
39. Hedrick TL, McElearney ST, Smith RL, Evans HL, Pruett TL, Sawyer RG. Duration of antibiotic therapy for ventilator-associated pneumonia caused by non-fermentative gram-negative bacilli. Surg Infect (Larchmt). 2007; 8: 589-597.
40. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001; 29: 1109-1115.
41. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest. 2005; 128: 2706-2713.
42. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest. 2004; 125: 1791-1799.
43. Mueller EW, Croce MA, Boucher BA, et al. Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia. J Trauma. 2007; 63: 1329-1337.
44. Pugh RJ, Cooke RP, Dempsey G. Short course antibiotic therapy for Gram-negative hospital-acquired pneumonia in the critically ill. J Hosp Infect. 2010; 74: 337-343.
45. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000; 162: 505-511.
46. Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology. 1991; 100: 1737-1742.
47. Taylor E, Dev V, Shah D, Festekjian J, Gaw F. Complicated appendicitis: is there a minimum intravenous antibiotic requirement? A prospective randomized trial. Am Surg. 2000; 66: 887-890.
48. Corey GR, Stryjewski ME, Everts RJ. Short-course therapy for bloodstream infections in immunocompetent adults. Int J Antimicrob Agents. 2009; 34( suppl 4): S47-S51.
49. Corona A, Wilson AP, Grassi M, Singer M. Short-course monotherapy strategy for treating bacteremia in the critically ill. Minerva Anestesiol. 2006; 72: 841-857.
50. Ehni WF, Reller LB. Short-course therapy for catheter-associated Staphylococcus aureus bacteremia. Arch Intern Med. 1989; 149: 533-536.
51. Malanoski GJ, Samore MH, Pefanis A, Karchmer AW. Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch Intern Med. 1995; 155: 1161-1166.
52. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44( suppl 2): S27-S72.
53. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171: 388-416.
54. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010; 50: 133-164.
55. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49: 1-45.
56. Kieninger AN, Lipsett PA. Hospital-acquired pneumonia: pathophysiology, diagnosis, and treatment. Surg Clin North Am. 2009; 89: 439-461, ix.
57. Craven DE, Palladino R, McQuillen DP. Healthcare-associated pneumonia in adults: management principles to improve outcomes. Infect Dis Clin North Am. 2004; 18: 939-962.
58. Lujan M, Gallego M, Rello J. Healthcare-associated infections. A useful concept? Curr Opin Crit Care. 2009; 15: 419-424.
59. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin. 2004; 20: 555-563.
60. El Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006; 332: 1355.
61. File TM Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother. 2007; 60: 112-120.
62. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med. 2004; 98: 708-720.
63. Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther. 1999; 6: 217-222.
64. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother. 2004; 54: 515-523.
65. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP, Athanassa Z, Falagas ME. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs. 2008; 68: 1841-1854.
66. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007; 120: 783-790.
67. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA. 1998; 279: 365-370.
68. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA. 2001; 286: 49-56.
69. Pankuch GA, Davies TA, Jacobs MR, Appelbaum PC. Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents. Antimicrob Agents Chemother. 2002; 46: 42-46.
70. Pankuch GA, Jacobs MR, Appelbaum PC. MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. 1996; 40: 2071-2074.
71. Pankuch GA, Jacobs MR, Appelbaum PC. Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials. J Antimicrob Chemother. 2003; 51: 443-446.
72. Pankuch G, Jacobs M, Appelbaum P. Antipneumococcal activity of ertapenem compared to nine other compounds by time-kill [abstract E-800]. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001: 184.
73. Pankuch G, Jacobs M, Appelbaum P. Time-kill analysis of the antipneumococcal activity of daptomycin compared with 8 other agents. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002: 161.
74. Pankuch G, Jacobs MR, Appelbaum PC. Post-antibiotic effect of garenoxacin against gram-positive and gram-negative organisms [abstract A-496]. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002: 42.
75. Bast DJ, Dresser L, Duncan CL, et al. Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice. J Chemother. 2006; 18: 634-640.
76. Chiavolini D, Pozzi G, Ricci S. Animal models of Streptococcus pneumoniae disease. Clin Microbiol Rev. 2008; 21: 666-685.
77. Lacy MK, Nicolau DP, Banevicius MA, Nightingale CH, Quintiliani R. Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model. J Antimicrob Chemother. 1999; 44: 477-481.
78. Montravers P, Fagon JY, Chastre J, et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis. 1993; 147: 38-44.
79. File TM Jr, Niederman MS. Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am. 2004; 18: 993-1016, xi.
80. Dennesen PJ, van der Ven AJ, Kessels AG, Ramsay G, Bonten MJ. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med. 2001; 163: 1371-1375.
81. Vidaur L, Gualis B, Rodriguez A, et al. Clinical resolution in patients with suspicion of ventilator-associated pneumonia: a cohort study comparing patients with and without acute respiratory distress syndrome. Crit Care Med. 2005; 33: 1248-1253.
82. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis. 1991; 143: 1121-1129.
83. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med. 2003; 31: 676-682.
84. Paladino JA. Pharmacoeconomic comparison of sequential IV/oral ciprofloxacin versus ceftazidime in the treatment of nosocomial pneumonia. Can J Hosp Pharm. 1995; 48: 276-283.
85. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med. 1991; 91: 462-470.
86. Basoli A, Chirletti P, Cirino E, et al. A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs > or = 5 days in community-acquired intraabdominal infection. J Gastrointest Surg. 2008; 12: 592-600.
87. Lennard ES, Dellinger EP, Wertz MJ, Minshew BH. Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. Ann Surg. 1982; 195: 19-24.
88. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003; 82: 333-339.
89. Thomas MG, Morris AJ. Cannula-associated Staphylococcus aureus bacteraemia: outcome in relation to treatment. Intern Med J. 2005; 35: 319-330.
90. Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis. 1992; 14: 75-82.
91. Abraham J, Mansour C, Veledar E, Khan B, Lerakis S. Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J. 2004; 147: 536-539.
92. Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol. 1997; 30: 1072-1078.
93. Fowler VG Jr, Sanders LL, Kong LK, et al. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis. 1999; 28: 106-114.